The drug candidate is datopotamab deruxtecan, an experimental therapy for locally advanced or metastatic non-small cell lung cancer in patients who have been treated with another chemotherapy — such as docetaxel, the standard treatment that is in short supply.
In a news release, AstraZeneca said the study will “continue as planned to assess overall survival with greater maturity.” No new safety concerns were noted in the phase 3 trial, and “some Grade 5 events [deaths] were observed.”
The candidate met its endpoint of progression-free survival.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
